CellGenix® Products per Cell Type

T cells play a central role in cell-mediated immunity. T cell immunotherapy for cancer, chronic infection, and autoimmunity is a rapidly growing field with very promising results in clinical trials. There are currently four types of therapies: chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TILs), regulatory T cells (Treg) and T cell receptor (TCR) engineered T cells.

DCs represent unique antigen-producing cells capable of sensitizing T cells to antigens. They play a central role in the regulation of innate and adaptive immunity. DC therapy represents a new and promising immunotherapeutic approach for treatment of different types of cancer.

NK cells are a subset of cytotoxic lymphocytes involved in the innate immune system. They play a major role in the host-rejection of both tumors and virally infected cells. Immunotherapy, based on NK cell infusion, is a potential adjuvant treatment for many cancers.

HSCs are widely used for transplantation after high-dose chemotherapy of lymphoma, leukemia and certain immune-deficiency illnesses.

ES and iPS cells can differentiate into all cell types of the human body and have the capacity to self-renew. Potential therapeutic applications include basic research, drug testing and regenerative therapies.

ES and iPS cells are in addition used as new cell sources for the generation of DC and T cell therapies.

MSCs are multipotent stem cells that can be differentiated into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, pancreatic islets cells and neuronal cells.

They hold great therapeutic promise in the field of cell-based tissue engineering and regenerative medicine. MSCs are being used for the prevention or treatment of GvHD after allogeneic blood stem cell transplantation. Their immunomodulatory properties are furthermore employed in autoimmune diseases such as diabetes and Crohn’s disease.

Chondrocytes are the only cell type resident in the cartilage. Chondrocytes are, for example, used for the generation of articular cartilage injuries in the knee (Autologous Chondrocyte Transplantation, ACT).